CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future - PubMed (original) (raw)
Review
. 2002 Aug 12;21(35):5427-40.
doi: 10.1038/sj.onc.1205600.
Affiliations
- PMID: 12154405
- DOI: 10.1038/sj.onc.1205600
Review
CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future
Manel Esteller. Oncogene. 2002.
Abstract
We have come a long way since the first reports of the existence of aberrant DNA methylation in human cancer. Hypermethylation of CpG islands located in the promoter regions of tumor suppressor genes is now firmly established as an important mechanism for gene inactivation. CpG island hypermethylation has been described in almost every tumor type. Many cellular pathways are inactivated by this type of epigenetic lesion: DNA repair (hMLH1, MGMT), cell cycle (p16(INK4a), p15(INK4b), p14(ARF)), apoptosis (DAPK), cell adherence (CDH1, CDH13), detoxification (GSTP1), etc em leader However, we still know little of the mechanisms of aberrant methylation and why certain genes are selected over others. Hypermethylation is not an isolated layer of epigenetic control, but is linked to the other pieces of the puzzle such as methyl-binding proteins, DNA methyltransferases and histone deacetylase, but our understanding of the degree of specificity of these epigenetic layers in the silencing of specific tumor suppressor genes remains incomplete. The explosion of user-friendly technologies has given rise to a rapidly increasing list of hypermethylated genes. Careful functional and genetic studies are necessary to determine which hypermethylation events are truly relevant for human tumorigenesis. The development of CpG island hypermethylation profiles for every form of human tumors has yielded valuable pilot clinical data in monitoring and treating cancer patients based in our knowledge of DNA methylation. Basic and translational will both be needed in the near future to fully understand the mechanisms, roles and uses of CpG island hypermethylation in human cancer. The expectations are high.
Similar articles
- A gene hypermethylation profile of human cancer.
Esteller M, Corn PG, Baylin SB, Herman JG. Esteller M, et al. Cancer Res. 2001 Apr 15;61(8):3225-9. Cancer Res. 2001. PMID: 11309270 - Promoter hypermethylation profile of kidney cancer.
Dulaimi E, Ibanez de Caceres I, Uzzo RG, Al-Saleem T, Greenberg RE, Polascik TJ, Babb JS, Grizzle WE, Cairns P. Dulaimi E, et al. Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3972-9. doi: 10.1158/1078-0432.CCR-04-0175. Clin Cancer Res. 2004. PMID: 15217927 - Dormant hypermethylated tumour suppressor genes: questions and answers.
Esteller M. Esteller M. J Pathol. 2005 Jan;205(2):172-80. doi: 10.1002/path.1707. J Pathol. 2005. PMID: 15643671 Review. - Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours.
Esteller M, Herman JG. Esteller M, et al. J Pathol. 2002 Jan;196(1):1-7. doi: 10.1002/path.1024. J Pathol. 2002. PMID: 11748635 Review.
Cited by
- MGMT and MLH1 methylation in Helicobacter pylori-infected children and adults.
Alvarez MC, Santos JC, Maniezzo N, Ladeira MS, da Silva AL, Scaletsky IC, Pedrazzoli J Jr, Ribeiro ML. Alvarez MC, et al. World J Gastroenterol. 2013 May 28;19(20):3043-51. doi: 10.3748/wjg.v19.i20.3043. World J Gastroenterol. 2013. PMID: 23716983 Free PMC article. - Krüppel-like factor 4 promotes survival and expansion in acute myeloid leukemia cells.
Lewis AH, Bridges CS, Punia VS, Cooper AFJ, Puppi M, Lacorazza HD. Lewis AH, et al. Oncotarget. 2021 Feb 16;12(4):255-267. doi: 10.18632/oncotarget.27878. eCollection 2021 Feb 16. Oncotarget. 2021. PMID: 33659038 Free PMC article. - AIM1 promoter hypermethylation as a predictor of decreased risk of recurrence following radical prostatectomy.
Rosenbaum E, Begum S, Brait M, Zahurak M, Maldonado L, Mangold LA, Eisenberger MA, Epstein JI, Partin AW, Sidransky D, Hoque MO. Rosenbaum E, et al. Prostate. 2012 Jul 1;72(10):1133-9. doi: 10.1002/pros.22461. Epub 2011 Nov 29. Prostate. 2012. PMID: 22127895 Free PMC article. - Epigenetic Regulation in Breast Cancer.
Nam HJ, Baek SH. Nam HJ, et al. Adv Exp Med Biol. 2021;1187:103-119. doi: 10.1007/978-981-32-9620-6_5. Adv Exp Med Biol. 2021. PMID: 33983575 - Phase 2 study of dose-intense temozolomide in recurrent glioblastoma.
Norden AD, Lesser GJ, Drappatz J, Ligon KL, Hammond SN, Lee EQ, Reardon DR, Fadul CE, Plotkin SR, Batchelor TT, Zhu JJ, Beroukhim R, Muzikansky A, Doherty L, Lafrankie D, Smith K, Tafoya V, Lis R, Stack EC, Rosenfeld MR, Wen PY. Norden AD, et al. Neuro Oncol. 2013 Jul;15(7):930-5. doi: 10.1093/neuonc/not040. Epub 2013 Apr 3. Neuro Oncol. 2013. PMID: 23553268 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous